Krebs Biochemicals and Industries cash flow

Latest FY26

Cash from operations: −₹1.9cr−₹7.9 cr in FY25
Capital spending: ₹4.0cr−22.1% on FY25
Free cash flow: −₹5.9cr−₹13.0 cr in FY25
Cash from financing: ₹5.5cr−56.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	6.4	6.7	6.8	6.6
	—	7.1	5.9	4.7	3.0
	—	0.2	0.0	0.0	0.0
	—	0.0	−0.1	0.0	0.0
	—	0.3	3.8	2.1	13.6
	—	0.2	1.9	−1.4	0.4
	—	0.1	−0.3	−0.2	−0.2
	—	−0.0	2.8	−2.7	0.0
	—	0.2	−1.2	0.6	5.5
	—	−0.5	−0.9	−1.1	−0.3
	—	−2.9	−0.8	3.7	−22.6
	—	4.2	4.2	3.7	−5.7
	—	−0.5	−2.4	5.6	−2.5
	—	−0.1	−0.3	−0.1	0.0
	—	0.0	0.0	−0.1	0.2
	—	0.1	−0.1	0.4	0.3
Cash from operating activities
	−13.3	−16.9	−26.9	−19.7	−24.7
	—	15.0	19.0	22.0	−1.8
	—	−1.9	−7.9	2.3	−26.5
	—	0.0	0.0	0.0	0.0
	—	−1.9	−7.9	2.3	−26.5
Cash from investing activities
	—	4.0	5.1	7.8	10.9
	—	0.4	0.2	0.0	0.0
	—	−3.6	−5.0	−7.8	−10.9
Cash from financing activities
	—	10.3	41.0	10.3	40.3
	—	−2.3	22.3	0.0	0.0
	—	7.1	5.9	4.7	3.0
	—	5.5	12.9	5.6	37.3
	—	−0.0	0.0	0.1	−0.0
	—	−0.0	0.0	0.1	−0.0
	—	—	—	0.1	0.1
Reference items
	−1.7	−5.5	−15.0	−8.7	−15.8
	−6.2%	−23.0%	−34.7%	−17.3%	−30.3%
	−5.9	−5.9	−13.0	−5.5	−37.4
	—	−0.4	−0.2	−0.0	—
	−₹2.75	−₹2.75	−₹6.04	−₹2.56	−₹17.33
	—	0.11×	0.29×	−0.12×	1.07×
	—	0.0	0.0	0.0	0.0
	—	7.1	5.9	4.7	3.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KREBSBIO₹59.15

Krebs Biochemicals and Industries Limited

· Pharma & Health

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹128 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	6.6	6.8	6.7	6.4	—
+ Finance Costs	3.0	4.7	5.9	7.1	—
+ Other Non-cash Items	0.0	0.0	0.0	0.2	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-0.1	0.0	—
Changes in Working Capital
+ Inventories	13.6	2.1	3.8	0.3	—
+ Trade Receivables — Current	0.4	-1.4	1.9	0.2	—
+ Other Financial Assets — Current	-0.2	-0.2	-0.3	0.1	—
+ Other Financial Assets — Non-current	0.0	-2.7	2.8	-0.0	—
+ Other Current Assets	5.5	0.6	-1.2	0.2	—
+ Other Non-current Assets	-0.3	-1.1	-0.9	-0.5	—
+ Trade Payables — Current	-22.6	3.7	-0.8	-2.9	—
+ Other Financial Liabilities — Current	-5.7	3.7	4.2	4.2	—
+ Other Current Liabilities	-2.5	5.6	-2.4	-0.5	—
+ Other Non-current Liabilities	0.0	-0.1	-0.3	-0.1	—
+ Provisions — Current	0.2	-0.1	0.0	0.0	—
+ Provisions — Non-current	0.3	0.4	-0.1	0.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-24.7	-19.7	-26.9	-16.9	-13.3
+ Total Adjustments (incl. Working Capital)	-1.8	22.0	19.0	15.0	—
Cash from Operations (pre-tax)	-26.5	2.3	-7.9	-1.9	—
+ Income Taxes Paid	0.0	0.0	0.0	0.0	—
Cash from Operating Activities	-26.5	2.3	-7.9	-1.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	10.9	7.8	5.1	4.0	—
+ Disp of Fixed Assets	0.0	0.0	0.2	0.4	—
Cash from Investing Activities	-10.9	-7.8	-5.0	-3.6	—
Cash from Financing Activities
+ Proceeds from Borrowings	40.3	10.3	41.0	10.3	—
+ Repayment of Borrowings	0.0	0.0	22.3	-2.3	—
+ Interest Paid	3.0	4.7	5.9	7.1	—
Cash from Financing Activities	37.3	5.6	12.9	5.5	—
Net Changes in Cash (pre-FX)	-0.0	0.1	0.0	-0.0	—
Net Changes in Cash	-0.0	0.1	0.0	-0.0	—
Closing Cash	0.1	0.1	—	—	—
Reference Items
EBITDA	-15.8	-8.7	-15.0	-5.5	-1.7
EBITDA Margin %	-30.27	-17.30	-34.70	-22.97	-6.23
Free Cash Flow (CFO − Capex)	-37.4	-5.5	-13.0	-5.9	-5.9
Free Cash Flow to Equity	—	-0.0	-0.2	-0.4	—
Free Cash Flow per Basic Share	-17.33	-2.56	-6.04	-2.75	-2.75
Cash Flow to Net Income	1.07	-0.12	0.29	0.11	—
Cash Paid for Taxes	0.0	0.0	0.0	0.0	—
Cash Paid for Interest	3.0	4.7	5.9	7.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.